NCT00556660View on ClinicalTrials.gov

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions

Alzheimer Disease

Interventions

DRUG

[123I] AV-151

To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects

Trial Locations (2)

06510

Institute for Neurodegenerative Disorders, New Haven

Molecular NeuroImaging, LLC, New Haven

All Listed Sponsors

lead

Institute for Neurodegenerative Disorders

OTHER

NCT00556660 - Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects | Biotech Hunter | Biotech Hunter